What effects have ACE inhibitors had on reducing proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy?
A randomized controlled trial conducted in 2010 found that lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. The study, conducted by Amara et al., found that lisinopril improved urine protein/creatinine ratios, urine urea/creatinine ratios, and urine β2-microglobulin/creatinine ratios. Additionally, it was found that lisinopril increased serum albumin levels, reduced serum urea and creatinine levels, and reduced urine β2-microglobulin levels. The study concluded that lisinopril is an effective treatment for reducing proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. 